By discover and develop innovative biological MSC stem cells therapies and make them accessible to patients throughout the world.
By keeping our patients’ and customers’ safety and well-being at the core of everything we do.
By partnering with leading hospitals and healthcare professionals, and academia.
StemMedical® has spent years modifying and perfecting a commercially viable stem cell-enriched fat grafting solution for cosmetic treatments and now expanding into regenerative therapies and anti-inflammatory conditions.
Our founder, Dr. Stig-Frederik Trojahn Kølle, acknowledged the benefits of using a patient’s own fat for cosmetic treatments (e.g., breast augmentation, facial filling, wrinkle treatment and skin rejuvenation), as this material will always be biocompatible, natural appearing, non-immunogenic and versatile.
However, the transplanted fat graft is unpredictable and often has low survival. Thus, several procedures are needed to achieve an acceptable cosmetic outcome. Moreover, such transplants may not result in patient satisfaction and may not be a viable option for all people (e.g., thin people).
Inspired by scientific findings, StemMedical® was established in 2014 in Copenhagen, Denmark to begin modifying and perfecting a commercially viable stem cell-enriched fat grafting solution for various cosmetic treatments.
After targeted developmental work, we are now able to offer what we believe is a safe, natural, reliable, effective, and permanent fat grafting solution tailored to and around the individual patient. This treatment solution provides huge advantages over current artificial, synthetic, temporary, and unreliable cosmetic solutions.
We are proud to be pioneers of this new treatment regimen in modern plastic surgery and are committed to serving our patients and customers at the highest standards to always ensure satisfaction across the board while working hard to make the innovative treatments accessible to as many people as possible both geographically and economically.
Klaus Langhoff-Roos has held leading positions in Novo Nordisk for almost two decades across the value chain and key geographies.
He adds significant business acumen and launch experience to StemMedical having been responsible for the launches of both Ozempic® and Rybelsus®.
Over the last couple of years, his role has been to build Novo Nordisk’s strategy and commercial platform in stem cell therapy.
Dr. Fred Koelle
Stig-Frederik has been spearheading the R&D and clinical trial programs at StemMedical® since founding the company. Furthermore, he oversees the company’s stem cell production activities.
Stig-Frederik is a certified plastic surgeon from Copenhagen University Hospital, Rigshospitalet. He holds a PhD and has worked in Plastic and Reconstructive Surgery and Stem Cell Technology since 2009.
Marc Fauerby Lange
Marc is responsible for all commercial activities.
Marc has an comprehensive background as business consultant with the overarching theme of accelerating growth companies and transform enterprises supporting owners, managements and board of directors achieving the full potential of their bright innovations and bold ambitions within multiple sectors.
Peter has been responsible for all the company’s administrative, financial, and operational activities since co-founding the company.
Prior to joining StemMedical®, Peter worked for Royal Dutch Shell in various roles spanning business transformation, business development and trading.
Lasse is responsible for all the company’s administrative and financial activities.
Prior to joining StemMedical®, Lasse has previously held positions at Boston Consulting Group and the medical company Coloplast.
Board of directors
Stig Løkke Pedersen
Stig-Frederik Trojahn Kølle
Anders Christian Wolf Kølle
PhD, Research Fellow Harvard